4.21
Immuneering Corp Aktie (IMRX) Neueste Nachrichten
What analysts say about Immuneering Corporation stockFree Stock Market Return Analysis - Autocar Professional
What drives Immuneering Corporation stock priceFastest-growing stock picks - jammulinksnews.com
Analysts Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $13.25 - Defense World
Is Immuneering Corporation a good long term investmentSuperior stock growth - jammulinksnews.com
What makes Immuneering Corporation stock price move sharplyTop Gaining Low Risk Assets - Newser
Why Immuneering Corporation stock attracts strong analyst attentionShort Term Profit Focus - Newser
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Revolutionary Cancer Drug Gets Patent Protection Until 2042: Clinical Data Shows 94% Survival vs 67% Standard Care - Stock Titan
Immuneering director Hausman buys IMRX stock worth $19,862 By Investing.com - Investing.com South Africa
Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock By Investing.com - Investing.com South Africa
Immuneering director Hausman buys IMRX stock worth $19,862 - Investing.com
Insider Buying: Thomas Schall Acquires Additional Shares of Immu - GuruFocus
Immuneering (IMRX) Soars 10.66% on Positive Trial Data, Insider Buying - AInvest
At $3.02 Price, Immuneering Corp (IMRX) Is Sitting And Waiting - Stocksregister
Jefferies raises Immuneering price target to $3.50 from $1.50 on cancer data - Investing.com
Immuneering (IMRX) CBO Brakewood buys $4804 in shares - Investing.com
Immuneering (IMRX) director Feinberg buys $63k in shares - Investing.com
Immuneering (IMRX) CEO Zeskind buys $50k+ in shares - Investing.com
Immuneering (NASDAQ:IMRX) Receives Buy Rating from Needham & Company LLC - Defense World
Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus
Chardan Capital Maintains Buy Rating on IMRX with $13 Price Targ - GuruFocus
Metric Deep Dive: Understanding La Rosa Holdings Corp (LRHC) Through its Ratios - DWinneX
Financial Analysis: TNL Mediagene (TNMG)’s Ratios Unveil Key Insights - DWinneX
Immuneering (IMRX) Price Target Raised by Mizuho Following Positive Trial Data | IMRX Stock News - GuruFocus
Immuneering stock price target raised to $10 at Mizuho on cancer drug data - Investing.com
Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - Investing.com India
Immuneering's Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - MENAFN.com
Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer - TipRanks
Immuneering stock rises after positive pancreatic cancer trial data - Investing.com
Immuneering (IMRX) Reports Promising Phase 2a Trial Results for Pancreatic Cancer Treatment | IMRX Stock News - GuruFocus
Pancreatic Cancer Breakthrough: New Drug Shows 94% Survival Rate vs 67% Standard Care in Phase 2a Trial - Stock Titan
Immuneering Stock Soars 25.74% on Promising Cancer Trial Results - AInvest
Immuneering Corp holds annual stockholder meeting By Investing.com - Investing.com Canada
Immuneering Corp holds annual stockholder meeting - Investing.com Australia
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - The Manila Times
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - GlobeNewswire Inc.
Two Sigma Investments LP Purchases 10,126 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World
Immuneering Co. (NASDAQ:IMRX) Stock Position Reduced by Millennium Management LLC - Defense World
Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Needham Maintains Buy Rating on IMRX with Price Target of $9.00 - GuruFocus
Full Immuneering Leadership Team Reveals Latest Pipeline Updates at Prestigious Jefferies Conference - Stock Titan
Immuneering Corporation to Present at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq
‘Take the Plunge,’ Says Top Investor About Intel Stock - The Globe and Mail
Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.0 - GuruFocus
Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst - GuruFocus
Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst | IMRX Stock News - GuruFocus
21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP - Defense World
Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.00 | IMRX Stock News - GuruFocus
Immuneering Corp. Reports Promising Q1 2025 Results - TipRanks
Immuneering (IMRX) Stock Rating and Price Target Update | IMRX S - GuruFocus
Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks
Immuneering Corp SEC 10-Q Report - TradingView
Immuneering Reports Breakthrough: Cancer Drug Achieves 13-Month Survival in Late-Stage Pancreatic Cancer Patient - Stock Titan
IMRXImmuneering Corp Latest Stock News & Market Updates - Stock Titan
Why imrx price is going down right now - AInvest
Charting the Course: Immuneering Corp’s IMRX Stock Prospects - investchronicle.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):